FibroBiologics Presents Data From Dermal Fibroblast Spheroid-Based Treatment Of Chronic Wounds In A Diabetes Mouse Model At Advanced Wound Care Summit USA
FibroBiologics Presents Data From Dermal Fibroblast Spheroid-Based Treatment Of Chronic Wounds In A Diabetes Mouse Model At Advanced Wound Care Summit USA
FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today data from its latest study in a diabetes mouse model on the potential therapeutic efficacy of dermal fibroblast spheroids in treating chronic wounds. These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.
Fibrobiologics, Inc.（納斯達克股票代碼：FBLG）（“Fibrobiologics”）是一家臨床階段的生物技術公司，擁有150多項專利，正在申請使用成纖維細胞和成纖維細胞衍生材料開發治療慢性病的療法和潛在療法。該公司今天公佈了其在糖尿病小鼠模型中關於皮膚成纖維細胞球體治療慢性傷口潛在治療效果的最新研究數據。這些發現將在4月16日至17日在馬薩諸塞州波士頓舉行的美國高級傷口護理峯會上通過口頭和海報展示來公佈。
Diabetic foot ulcers (DFUs) are prevalent in individuals with diabetes, with approximately 33 million people impacted globally. DFUs pose significant challenges for patients and the healthcare system due to impaired healing mechanisms associated with hyperglycemia, cellular senescence, and other comorbidities associated with diabetes. FibroBiologics' research aims to address this issue by investigating the potential of using human dermal fibroblast (HDF) spheroids in promoting and accelerating the wound healing process in diabetic patients.
糖尿病足潰瘍（DFU）在糖尿病患者中很常見，全球約有3,300萬人受到影響。由於與高血糖、細胞衰老和其他與糖尿病相關的合併症相關的癒合機制受損，DFU對患者和醫療保健系統構成了重大挑戰。Fibrobiologics的研究旨在通過研究使用人體皮膚成纖維細胞（HDF）球體促進和加速糖尿病患者傷口癒合過程的可能性來解決這個問題。
The study, led by a team of researchers including FibroBiologics' Chief Scientific Officer, Hamid Khoja, Ph.D., utilized a diabetic mouse model to evaluate the therapeutic effects of HDF spheroids on mice with wounds resembling DFUs.
這項研究由包括Fibrobiologics首席科學官哈米德·霍賈博士在內的一組研究人員領導，利用糖尿病小鼠模型評估了HDF球體對傷口類似於DFU的小鼠的治療作用。
Key findings from the study include:
該研究的主要發現包括：
- Acceleration of wound healing with a 60% decrease in relative wound area within 4 days post-treatment with a single administration of HDF spheroids compared to standard of care treatment control.
- Upregulation of pro-inflammatory cytokines such as interferon-gamma (IFN-γ), interleukins IL-1), and tumor necrosis factor-alpha (TNF-α), along with anti-inflammatory cytokines IL-6 and IL-10, indicating modulation of the wound microenvironment conducive to healing.
- Increased levels of vascular endothelial growth factors (VEGF) and endothelial growth factor receptors (EGFR), suggesting enhanced revascularization and re-epithelialization in HDF-treated wounds.
- Immunohistochemical analysis revealing the presence of markers indicative of fibroblast and endothelial proliferation, active cell proliferation, angiogenesis, and macrophage proliferation in HDF-treated wounds.
- 與標準護理治療控制相比，單次施用 HDF 球體，在治療後 4 天內，傷口相對面積減少 60%，加速傷口癒合。
- 上調促炎細胞因子，例如干擾素伽瑪（IFN-γ型）、白介素IL-1）和腫瘤壞死因子-α（TNF-α），以及抗炎細胞因子IL-6和 IL-10，這表明傷口微環境的調節有利於癒合。
- 血管內皮生長因子（VEGF）和內皮生長因子受體（EGFR）水平升高，提示經HDF治療的傷口血運重建和再上皮化得到增強。
- 免疫組織化學分析顯示，在經HDF治療的傷口中，存在表明成纖維細胞和內皮增生、活性細胞增殖、血管生成和巨噬細胞增殖的標誌物。
"These results support the potential of HDF spheroids to expedite the healing process of chronic wounds associated with diabetes," said Dr. Khoja. "Our findings underscore the importance of further exploration and development of fibroblast spheroid-based therapies for clinical applications, particularly in patients with diabetic foot ulcers."
霍賈博士說：“這些結果支持HDF球體有可能加快與糖尿病相關的慢性傷口的癒合過程。”“我們的發現突顯了進一步探索和開發基於成纖維細胞球體的療法對於臨床應用的重要性，特別是在糖尿病足潰瘍患者中。”
Details of the presentations are as follows:
演講詳情如下：
Oral Presentation:
口頭陳述：
Presentation Title: Fibroblast Spheroid-mediated Accelerated Chronic Wound Healing in a Diabetic Mouse Model
Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics
Session Title: Research and Development - Biologics
Session Date and Time: April 16, 2024, at 12:30 p.m. Eastern Standard Time
演講題目：糖尿病小鼠模型中成纖維細胞球體介導的加速慢性傷口癒合
演講者：Hamid Khoja，博士，Fibrobiologics 首席科學官
會議標題：研究與開發-生物製劑
會議日期和時間：2024 年 4 月 16 日美國東部標準時間下午 12:30
Poster Presentation:
海報演示：
Presentation Title: Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model
Presenter: Subhiksha Raghuram, MS, MD, Associate Scientist, FibroBiologics
Poster Session: Available Virtually
演講題目：糖尿病小鼠模型中基於皮膚成纖維細胞球體的慢性傷口治療
演講者：Subhiksha Raghuram，MS，醫學博士，Fibrobiologics副科學家
海報會議：虛擬可用
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
欲了解更多信息，請訪問Fibrobiologics的網站或發送電子郵件至Fibrobiologics：info@fibrobiologics.com。